Bicycle Therapeutics Limited
Meditrina Building
Babraham Research Campus
Cambridge
CB22 3AT
United Kingdom
Tel: 44-0-1223-497-390
Fax: 44-0-7798-791-337
Website: http://www.bicycletherapeutics.com/
182 articles about Bicycle Therapeutics Limited
-
Bicycle Therapeutics Announces Appointment of Nigel Crockett, Ph.D., as Chief Business Officer
10/29/2019
Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the appointment of Nigel Crockett, Ph.D., as the company’s Chief Business Officer, replacing Peter Leone.
-
Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford University’s Oxford Drug Discovery Institute
10/22/2019
Bicycle to collaborate with ODDI, an organization with deep expertise in the molecular pathology of Alzheimer’s disease and CNS drug development
-
Bicycle Therapeutics to Present New Translational Data for BT1718 and Preclinical Data for Other Bicycle® Toxin Conjugates at AACR-NCI-EORTC 2019
10/16/2019
New translational data will be presented for BT1718, the Company’s lead Bicycle® Toxin Conjugate (BTC) product candidate, which define enrollment criteria for identifying expansion cohorts in the Phase IIa part of the ongoing Phase I/IIa trial with BT1718.
-
Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress
9/28/2019
Bicycle Therapeutics plc announced the presentation of updated data from a Phase I/IIa trial conducted in collaboration with Cancer Research UK and evaluating BT1718 in an unselected group of patients with advanced solid tumors.
-
Bicycle Therapeutics to Present Updated Data from Phase I/IIa Trial Evaluating Lead Asset BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress
9/24/2019
Bicycle Therapeutics plc announced that updated data from the Phase I dose escalation portion of the Phase I/IIa trial evaluating the Company’s lead asset BT1718 in patients with advanced solid tumors will be presented at the European Society of Medical Oncology 2019 Annual Congress, September 27 – October 1 in Barcelona, Spain.
-
Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update
8/8/2019
Bicycle Therapeutics plc reported financial results for the second quarter ended June 30, 2019 and provided a clinical update.
-
Bicycle Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
8/1/2019
Bicycle Therapeutics plc announced that management will present at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, 2019 at 1:30 p.m. EDT in Boston, MA.
-
BioSpace Movers and Shakers, July 26
7/26/2019
Biotech and pharma companies bolster their executive leadership and boards of directors with this week's appointments. -
Bicycle Therapeutics Enhances Board of Directors
7/24/2019
Appoints pharmaceutical industry veteran Richard N. Kender, MBA, and life sciences financing professional Janice Bourque, MBA
-
Bicycle Therapeutics Announces Positive Topline Results from Oxurion’s Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
7/1/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the successful completion of Oxurion’s Phase I clinical trial evaluating the safety and tolerability of a single intravitreal injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor
-
Bicycle Therapeutics Announces Pricing of Initial Public Offering
5/23/2019
Bicycle Therapeutics plc announced the pricing of its initial public offering in the United States of 4,333,333 American Depositary Shares representing 4,333,333 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions.
-
A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
-
The company focuses on developing a novel class of drugs called Bicycles. Bicycles are fully synthetic short peptides constrained to form two loops—hence “bi” cycles—that stabilize their structural geometry.
-
BioSpace Movers and Shakers: May 10
5/10/2019
Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more. -
Bicycle Therapeutics Strengthens Clinical Team to Advance Expanding Pipeline
5/9/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, today announced two senior appointments to facilitate its expanding and advancing clinical pipeline. Lisa Mahnke, M.D., Ph.D., joins as Senior Vice President and Head of Clinical.
-
Bicycle Therapeutics Enters Neuroscience Arena through Collaboration with Dementia Discovery Fund
5/7/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, today announced a collaboration with the Dementia Discovery Fund (DDF) to use Bicycle technology for the development of novel therapeutics for neurodegenerative diseases.
-
A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.
-
4 Biotech Companies Announce IPO Plans
4/29/2019
Four biotech companies recently filed with the U.S. Securities and Exchange Commission their plans for initial public offerings (IPO). Let’s take a look. -
Bicycle Therapeutics to Present Immune Oncology CD137 Data on Multivalent and Tumor-targeted Bispecific Bicycles at Peptides Congress
4/24/2019
Bicycle Therapeutics announced that Punit Upadhyaya, Ph.D., Senior Scientist at Bicycle, will present at the 6th Annual Peptides Congress in London.
-
Bicycle Therapeutics and Oxurion Announce Full Enrollment in Phase I Trial for the Treatment of Diabetic Macular Edema
4/24/2019
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, and Oxurion today announced full enrollment of Oxurion’s Phase I trial designed to evaluate the safety of a single injection of THR-149, a novel Bicycle-based plasma kallikrein (PKal) inhibitor.